Professor Steve Nissen, Cleveland Clinic Foundation, Ohio, USA, reports data from a single ascending dose study investigating the safety and Lp(a) lowering effects of lepodisiran in patients without cardiovascular disease but with Lp(a) levels ≥75 nmol/L (≥30 mg/dL).
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)